Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

81.16USD
23 Sep 2016
Change (% chg)

$-0.13 (-0.16%)
Prev Close
$81.29
Open
$80.99
Day's High
$81.45
Day's Low
$80.77
Volume
824,382
Avg. Vol
1,212,942
52-wk High
$88.48
52-wk Low
$67.88

Latest Key Developments (Source: Significant Developments)

Eli Lilly Canada says Health Canada approves Taltz for treatment of moderate-to-severe plaque psoriasis
Tuesday, 21 Jun 2016 12:42pm EDT 

Eli Lilly Canada :Eli Lilly Canada says Health Canada has granted approval for Taltz for treatment of moderate-to-severe plaque psoriasis.  Full Article

Eli Lilly sets quarterly dividend of $0.51/shr
Monday, 20 Jun 2016 01:00pm EDT 

Eli Lilly And Co :Sets quarterly dividend of $0.51 per share.  Full Article

Eli Lilly and Co says German supreme court grants Lilly appeal in Alimta vitamin regimen patent lawsuit
Tuesday, 14 Jun 2016 06:15pm EDT 

Eli Lilly And Co : Eli lilly and co says german supreme court grants lilly appeal in alimta vitamin regimen patent lawsuit . Eli lilly and co says german supreme court returned case to court of appeal ( dusseldorf ) for further proceedings . Separate infringement proceeding and validity challenge with hexal ag will continue unaffected by this ruling . Eli lilly and co says separate infringement proceeding and validity challenge with hexal ag will continue unaffected by this ruling .German federal supreme court has granted appeal by eli lilly in case of eli lilly v. Actavis, vacating prior decision denying infringement.  Full Article

Lilly names Aarti Shah Chief Information Officer
Monday, 13 Jun 2016 01:00pm EDT 

Eli Lilly And Co: Aarti Shah named Chief Information Officer . Promotion of Aarti Shah , Ph.D., to Senior Vice President and Chief Information Officer effective July 1 .Shah has been global brand development leader for Immunology since 2013..  Full Article

Lilly says announces results from Monarch 1 trial of Abemaciclib monotherapy
Friday, 3 Jun 2016 05:45pm EDT 

Eli Lilly And Co - : Says safety and toxicity profile continuously dosed Abemaciclib was consistent with previous Phase 1 experience . Lilly announces results from monarch 1 trial of Abemaciclib monotherapy .Eli Lilly and Co says plans to publish further data from monarch 1 trial later this year.  Full Article

Adocia, Lilly announce positive results from BioChaperone Lispro U100 study
Tuesday, 31 May 2016 12:00pm EDT 

Eli Lilly And Co : Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin biochaperone lispro U100 in healthy Japanese subjects .Both BioChaperone Lispro and Humalog were similarly well tolerated; no new or unexpected safety findings were observed..  Full Article

Eli Lilly says can launch 20 new products from 2014-2023
Tuesday, 24 May 2016 06:30am EDT 

Eli Lilly And Co : Lilly details robust research and development pipeline to investment community . Could launch average of two new indications or line extensions for already-approved products per year during that same time period . Stated it has potential to launch 20 new products in 10 years beginning in 2014 and extending through 2023 ."research and development efforts focus on five therapeutic areas where company has assets and capabilities that enable it to compete successfully".  Full Article

Sandoz Canada launches PrSandoz Duloxetine, a generic version of Cymbalta
Tuesday, 17 May 2016 02:42pm EDT 

Sandoz Canada : Sandoz Canada launches PrSandoz Duloxetine, a generic version of Cymbalta, for treatment of depression and anxiety symptoms .PrSandoz Duloxetine is now available on Canadian market in two strengths, 30 mg or 60 mg.  Full Article

Eli Lilly and Co declares dividend
Monday, 2 May 2016 02:28pm EDT 

Eli Lilly and Co:Declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding common stock.Payable June 10, 2016, to shareholders of record at the close of business on May 13, 2016.  Full Article

Adocia and Lilly announce positive results from Phase 1b study of Lispro U100
Wednesday, 27 Apr 2016 12:00pm EDT 

Adocia SAS and Eli Lilly and Company:Adocia and Lilly announce positive results from a Phase 1b study of repeated administration of ultra-rapid biochaperone Lispro U100 in people with type 2 diabetes.  Full Article

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.